Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.39 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.33 |
| ▸ | LCK | P06239 | 1/20 | 0.33 |
| ▸ | FYN | P06241 | 1/20 | 0.33 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.31 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.31 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17049853 | 0.85 | TP53 (0.42) | TP53SLC7A5SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL18624675 | 0.82 | TP53 (0.40) | TP53SLC7A5FFAR3LCKFYN | |
| SCHEMBL3902662 | 0.81 | LMNA (0.36) | TP53SLC7A5FFAR3LCKFYN | |
| SCHEMBL8605204 | 0.78 | TP53 (0.47) | TP53SLC7A5ALDH1A1 | |
| SCHEMBL27600338 | 0.76 | SLC7A5 (0.59) | TP53SLC7A5SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL27600339 | 0.76 | SLC7A5 (0.59) | TP53SLC7A5SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL25575130 | 0.75 | TP53 (0.44) | TP53SLC7A5FFAR3LCKFYN | |
| SCHEMBL10570748 | 0.75 | TP53 (0.44) | TP53SLC7A5FFAR3LCKFYN | |
| Acetic Acid SCHEMBL27541991 | 0.75 | FFAR3 (0.47) | TP53SLC7A5FFAR3LCKFYN | |
| SCHEMBL24287053 | 0.74 | TP53 (0.38) | TP53SLC7A5SLC1A3SLC1A2SLC1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240072809-A1 | ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2024-02-29 | — | — | US | disclosed |
| US-11819551-B2 | ASGPR-binding compounds for the degradation of extracellular proteins | AVILAR THERAPEUTICS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| US-20230233689-A1 | Bifunctional Small Molecules to Target the Selective Degradation of Circulating Proteins | UNIV YALE (US) | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11819551-B2 | ASGPR-binding compounds for the degradation of extracellular proteins | ASGR1, ENGASE, FCGR2A | TP53 2592/4885SLC7A5 1484/4885FFAR3 1830/4885 |
| US-20230233689-A1 | Bifunctional Small Molecules to Target the Selective Degradation of Circulating Proteins | ASGR1, LDLR, FCGR2A | TP53 919/4885SLC7A5 452/4885FFAR3 1568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.